Navigation Links
AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17
Date:2/12/2013

ted in the fourth quarter of 2011.

Total contract revenue for the fourth quarter of 2012 was $59.1 million, an increase of 50% compared to total contract revenue of $39.4 million reported in the fourth quarter of 2011. Total contract revenue encompasses revenue from AMRI's Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing business components.

  • Discovery Services contract revenue for the fourth quarter was $10.6 million, an increase of 12% from $9.5 million in 2011.
  • Development/Small Scale Manufacturing contract revenue for the fourth quarter was $10.4 million, an increase of 41% from $7.3 million in 2011.
  • Large Scale Manufacturing contract revenue for the fourth quarter was $38.1 million, an increase of 69% from $22.6 million in 2011.
  • Royalty revenue in the fourth quarter of 2012 was $8.1 million, an increase of 13% from $7.2 million in the fourth quarter of 2011. Royalty revenue for the fourth quarter of 2012 includes royalties from the Allegra products as well as $1.4 million earned by the company on net sales of a generic product for which the company also manufactures the active pharmaceutical ingredient at its Rensselaer, N.Y. facility.

    Net income under U.S. GAAP was $1.9 million, or $0.07 per basic and diluted share, in the fourth quarter of 2012, compared to a U.S. GAAP net loss of $(24.4) million, or $(0.81) per basic and diluted share for the fourth quarter of 2011. During the fourth quarter of 2012, net income under U.S. GAAP includes the impact of non-cash long-lived asset impairment charges of $2.8 million, net of tax, or $0.09 per diluted share, and restructuring charges of approximately $0.6 million, net of tax, or $0.02 per diluted share, primarily related to the company's previously announced decision to close its Bothell, WA facility. Net income on an adjusted basis was $5.1 million or $0.17 per basic and diluted share.

    Full Year 2012 ResultsTotal
    '/>"/>

    SOURCE AMRI
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
    2. The In View Series Announces Plans for a New Series on 3D-Printing
    3. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
    4. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
    5. Murray Test Prep Announces the Launch of their Online Tutoring Services
    6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
    7. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
    8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
    9. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
    10. Spectrum Announces bioWorld Distribution Agreement
    11. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
    (Date:2/28/2015)... Increasing its efforts to resolve the ... three episodes of The GMO TRUTH podcast on both ITunes ... it continues its mission to discover the truth and change ... to “uncover the truth about the GMOs in our food ... Truth Podcast is an expansion of the documentary/investigative film-making methodology ...
    (Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
    (Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
    Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
    ... , ... assay • LEADseeker • SPA Imaging Beads, ... present in high levels in the pituitary and are processed into ... and β-endorphin. The various melanocyte stimulating hormones are known to activate ...
    ... , ... kinase assay • LEADseeker • chemiluminescence , , ... least 500 kinase and phosphatase enzymes exist, their activities having ... cascade in disease pathways such as inflammation and cancer, so ...
    ... , ... workspace • base set • differential expression analysis • principal components ... , ... advanced statistics on samples from a study on human ovarian cancer. ...
    Cached Biology Technology:The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 5Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Extended data analysis using DeCyder EDA 2Extended data analysis using DeCyder EDA 3Extended data analysis using DeCyder EDA 4Extended data analysis using DeCyder EDA 5Extended data analysis using DeCyder EDA 6Extended data analysis using DeCyder EDA 7Extended data analysis using DeCyder EDA 8Extended data analysis using DeCyder EDA 9Extended data analysis using DeCyder EDA 10
    (Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
    (Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
    (Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
    Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
    ... /PRNewswire-iReach/ -- Over the past several weeks and months there ... sites that discuss Pro Ana in any form or that ... like that promote dangerous conditions such as anorexia and bulimia, ... ) The premise is that they encourage, support ...
    ... YORK, JULY 10, 2013 Researchers at Memorial ... have developed a new method for identifying the ... within multicellular environments. The technique, named ... (CTAP), exploits the inability of vertebrate cells to ...
    ... depleting the Earth,s supply of oil are unwarranted, according to ... as opposed to the supply will reach its own ... painted pictures of everything from a calm development of alternatives ... world reaches its peak of oil production and then ...
    Cached Biology News:Pro Ana and Thinspiration Sites Under Attack 2Pro Ana and Thinspiration Sites Under Attack 3Stanford researchers say 'peak oil' concerns should ease 2Stanford researchers say 'peak oil' concerns should ease 3
    ... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
    Request Info...
    ... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
    LTBP-1 (E-20)...
    Biology Products: